Reuters logo
BRIEF-Protalix Biotherapeutics receives positive European opinion on orphan designation for PRX-102
November 13, 2017 / 12:13 PM / 7 days ago

BRIEF-Protalix Biotherapeutics receives positive European opinion on orphan designation for PRX-102

Nov 13 (Reuters) - Protalix Biotherapeutics Inc

* Protalix Biotherapeutics receives positive opinion for orphan designation for PRX-102 for the treatment of Fabry disease in the European Union Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below